An amino-benzosuberene analogue that inhibits tubulin assembly and demonstrates remarkable cytotoxicity
- 21 March 2012
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 3 (6) , 720-724
Abstract
The recent discovery of a small-molecule benzosuberene-based phenol that demonstrates remarkable picomolar cytotoxicity against selected human cancer cell lines and strongly inhibits tubulin polymerization (1–2 μM) inspired the design and synthesis of a variety of new, structurally diverse benzosuberene derivatives. An efficient synthetic route to functionalized benzosuberenes was developed. This methodology utilized a Wittig reaction, followed by a selective alkene reduction and ring-closing cyclization to form the core benzosuberone structure. This synthetic route facilitated the preparation of a 4-nitro-1-(3′,4′,5′-trimethoxyphenyl) benzosuberene derivative and its corresponding 4-amino analogue in good yield. The 4-amino analogue was a strong inhibitor of tubulin polymerization (1.2 μM), demonstrated enhanced cytotoxicity against the human cancer cell lines examined (GI50 = 33 pM against SK-OV-3 ovarian cancer, for example), and exhibited a concentration dependent disruption of a pre-established capillary-like network of tubules formed from human umbilical vein endothelial cells.Keywords
This publication has 34 references indexed in Scilit:
- Synthesis of 3-methoxy-9-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5H-benzo[7]annulen-4-ol, a potent antineoplastic benzosuberene derivative for anti-cancer chemotherapyTetrahedron Letters, 2012
- Synthesis of Benzocycloheptanones through Coupling of δ,ε-Unsaturated Chromium Carbene Complexes and 2-Alkynylbenzoyl DerivativesOrganic Letters, 2011
- The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting AgentsCancer Treatment Reviews, 2011
- A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessmentIntegrative Biology, 2011
- A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with OutcomeThyroid®, 2009
- A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)Expert Opinion on Investigational Drugs, 2009
- Antineoplastic Agents. 552. Oxidation of Combretastatin A-1: Trapping the o-Quinone Intermediate Considered the Metabolic Product of the Corresponding Phosphate ProdrugJournal of Natural Products, 2008
- Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4Cellular and Molecular Life Sciences, 1989
- Synthesis of structural analogues of 6,7,8,9-tetrahydro-3-hydroxy-2-methoxybenzocyclohepten-5-oneJournal of the Chemical Society, Perkin Transactions 1, 1979
- Ring Expansions and Contractions with Diazonium Betaines. I. Synthesis of Ketones by Ring Expansion of Methylenecycloalkanes with Arenesulfonyl AzidesThe Journal of Organic Chemistry, 1973